Absorption, distribution, metabolism, and excretion of the BMS-986365 ligand-directed degrader diastereomers, R,R-[14C]BMS-986409 and R,S-[14C]BMS-986410, following oral administration in combination with an intravenous microtracer in healthy male participants
Drug Metabolism and Disposition · 2026-11 · 100434
DOI: 10.1016/j.dmd.2026.100434 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Metabolism and Disposition, 2026-11. Verfasst von Robert L. Walsky und 10 weiteren Autor:innen. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Bristol-Myers Squibb Company.
Abstract (Originalsprache)
An absorption, distribution, metabolism, and excretion study was performed to determine pharmacokinetic parameters, mass balance, and metabolite profiles of the androgen receptor ligand-directed degrader BMS-986365, a 1:1 mixture of R,R -BMS-986409 and R,S -BMS-986410 diastereomers, in humans. This open-label, single-center, nonrandomized study had a 2-part design. In part A, 8 healthy males received a microtracer intravenous infusion of [ 14 C]BMS-986365 following an oral dose of unlabeled BMS-986365 resulting in a systemic plasma clearance of 15.4 L/h, a steady-state volume of distribution of 445 L, and a mean half-life of 20.2 hours. In part B, 16 healthy male participants received a 1:1 oral dose of R,R -[ 14 C]BMS-986409 and R,S- BMS-986410 (n=8), or R,S- [ 14 C]BMS-986410 and R,R -BMS-986409 (n=8). Following oral dosing of the BMS-986365 diastereomers, time to maximum plasma concentration was ∼3.0 hours, determined fraction absorbed was 0.74, fraction surviving gut metabolism was 0.27, and oral bioavailability was 15.3%. In plasma, the main circulating drug species were a disproportionate metabolite M16 (BMT-617315, N- dealkylation followed by oxidation; mean across both arms: 66.2%), M15 (BMT-617088, N -dealkylation followed by reduction; 12.6%), and parent BMS-986365 (8.5%). Mass balance showed fecal excretion as the primary route of elimination (91.5% of dose) for BMS-986365, with renal excretion being low (2.0% of dose). Part B mean recovery of the administered radioactivity was 93.8%. In vitro phenotyping indicated oxidative formation of M6 ( N -dealkylation), M15, and M16 from BMS-986365 was CYP3A mediated, and that the formation of M4 (glutarimide ring hydrolysis and cyclization) was chirally selective and arylacetamide deacetylase mediated, with an 8.7-fold higher exposure from R,S- [ 14 C]BMS-986410 compared with R,R -[ 14 C]BMS-986409. SIGNIFICANCE STATEMENT This study provides an understanding of the absorption, distribution, metabolism, and excretion of the racemic androgen receptor ligand-directed degrader BMS-986365, a 1:1 mixture of R,R -BMS-986409 and R,S- BMS-986410 diastereomers, following oral and microtracer intravenous administration in healthy male participants. In vivo clinical and in vitro phenotyping data allowed mechanistic insights into the pharmacokinetic properties of BMS-986365 and will help guide future studies evaluating drug-drug interactions, special populations such as hepatic or renal impairment, and metabolite safety.
Förderung
- Bristol-Myers Squibb Company
Zitieren
APA
Walsky, R. L., Cheng, S., Chen, L., Ye, M., Chen, J., Warren, V., Allentoff, A. J., Wen, B., Katyayan, K., Yerramilli, U., & Suryawanshi, S. (2026). Absorption, distribution, metabolism, and excretion of the BMS-986365 ligand-directed degrader diastereomers, R,R-[14C]BMS-986409 and R,S-[14C]BMS-986410, following oral administration in combination with an intravenous microtracer in healthy male participants. Drug Metabolism and Disposition, 100434. https://doi.org/10.1016/j.dmd.2026.100434
Vancouver
Walsky RL, Cheng S, Chen L, Ye M, Chen J, Warren V, et al. Absorption, distribution, metabolism, and excretion of the BMS-986365 ligand-directed degrader diastereomers, R,R-[14C]BMS-986409 and R,S-[14C]BMS-986410, following oral administration in combination with an intravenous microtracer in healthy male participants. Drug Metabolism and Disposition. 2026:100434. doi:10.1016/j.dmd.2026.100434
BibTeX
@article{Walsky2026,
author = {Walsky, Robert L. and Cheng, Shih-Hsun and Chen, Lin and Ye, Min and Chen, Jian and Warren, Vance and Allentoff, Alban J. and Wen, Bo and Katyayan, Kishore and Yerramilli, Usha and Suryawanshi, Satyendra},
title = {Absorption, distribution, metabolism, and excretion of the BMS-986365 ligand-directed degrader diastereomers, R,R-[14C]BMS-986409 and R,S-[14C]BMS-986410, following oral administration in combination with an intravenous microtracer in healthy male participants},
journal = {Drug Metabolism and Disposition},
year = {2026},
pages = {100434},
doi = {10.1016/j.dmd.2026.100434}
}
EUVIMED